Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial Summary: This Phase 1b trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of co-administering once-weekly subcutaneous cagrilintide (at various doses) with semaglutide 2.4 mg in participants for weight management
This piece is created using inputs from CompoundingAI
I want to start with orforglipron as its familiar at this point in time
Semaglutide stands out not because its trendy, but because it works
NSA, MH, HH, and EB analyzed and/or interpreted the data and prepared the first draft of the manuscript
Your healthcare team can help you distinguish between normal adjustment fatigue and signs that a dosing adjustment or medication switch is needed